Safety of anti-tumor necrosis factor agents in psoriatic arthritis - an update (Q38161956)

30 August 2017

0 references

Safety of anti-tumor necrosis factor agents in psoriatic arthritis - an update (English)

1 reference

30 August 2017

1 reference

Pietro Leccese

3

0 references

author name string

Carlo Palazzi

1

1 reference

30 August 2017

Salvatore D'Angelo

2

1 reference

30 August 2017

Angela Padula

4

1 reference

30 August 2017

Ignazio Olivieri

5

1 reference

30 August 2017

language of work or name

English

0 references

publication date

13 November 2013

1 reference

Expert Opinion on Drug Safety

30 August 2017

1 reference

30 August 2017

13

1 reference

30 August 2017

2

1 reference

30 August 2017

191-196

1 reference

Psoriatic arthritis: a systematic review

30 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.857655

Psoriatic arthritis: imaging techniques

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.857655

New insights in occult psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.857655

Psoriatic arthritis: treatment strategies using biologic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.857655

Psoriatic arthritis: treatment strategies using anti-inflammatory drugs and classical DMARDs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.857655

Biologic therapies in psoriasis: a new therapeutic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.857655

Pathogenetic and clinical rationale for TNF-blocking therapy in psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.857655

Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.857655

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.857655

Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.857655

Can we reduce the dosage of biologics in spondyloarthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.857655

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.857655

Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.857655

Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.857655

Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.857655

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.857655

Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.857655

Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.857655

Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.857655

Side effects of TNF-α blockers in patients with psoriatic arthritis: evidences from literature studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.857655

Role for interferon-gamma release assays in latent tuberculosis screening before TNF-α antagonist therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.857655

Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.857655

Management of rheumatic disease with comorbid HBV or HCV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.857655

Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.857655

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.857655

Cancer risk of anti-TNF-α at recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.857655

Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.857655

Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.857655

Overview of safety of non-biologic and biologic DMARDs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.857655

Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.857655

BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.857655

Effective Therapy with Anti-TNF- in Patients with Psoriatic Arthritis Is Associated with Decreased Levels of Metalloproteinases and Angiogenic Cytokines in the Sera and Skin Lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.857655

10.1517/14740338.2014.857655

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference